SP = $US1.50
Market Cap sitting at US58m
Cash (including short and long term investments) = approx $US77m
Therefore. current value attributed to future royalties, pipeline, patents and future developments = minus $US19m.
The market either has zero trust in the pipeline and/or management and/or it is time for Investor Relations to get out there and start peddling. In truth, it appears they are getting out there at Healthcare conferences, so the 2H2016 Phase 2a and Phase 2 trial results should prove to be inflection points (either way) for company.
Existing long term holders are not prepared to throw more money at this, but if I were a new investor, it would be a no-brainer - I'd see this as worthy of a roll of the dice.
- Forums
- ASX - By Stock
- BTA
- $20m cash injection - partial monetisation of Inavir royalties
$20m cash injection - partial monetisation of Inavir royalties, page-3
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
SPONSORED BY The Market Online